Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-01

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Interleukin-6 (IL-6), a pro-inflammatory cytokine, has been found to have a crucial role in the pathogenesis of Giant cel arteritis (GCA). Based on this rationale, several recent studies demonstrated the efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, for the treatment of patients with refractory GCA. Confirming previous reports,in a recent retrospective study the investigators successfully treated 10 patient with refractory GCA with TCZ. All patients achieved a complete disease remission evaluated by clinical, laboratory, and positron emission tomography (PET). In a considerable number of GCA patients treated with corticosteroids (CS) the therapy may be interrupted with no disease flares. No data are available on the management of patients achieving the remission with TCZ.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tocilizumab for Patients With Giant Cell Arteritis

NCT01450137

Giant Cell Arteritis

COMPLETED PHASE2

Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.

NCT01910038

Giant Cell Arteritis

COMPLETED PHASE2

Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab

NCT03745586

Giant Cell Arteritis

COMPLETED PHASE1/PHASE2

TocilizuMab discontinuAtion in GIant Cell Arteritis

NCT06037460

Giant Cell Arteritis

ACTIVE_NOT_RECRUITING PHASE3

Tocilizumab Plus a Short Prednisone Taper for GCA

NCT03726749

Giant Cell Arteritis

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design. Open-label, prospective, pilot study on patients with giant cell arteritis (GCA) resistant to corticosteroids (CS) .

Setting. Rheumatology department, Hospital of Prato, Prato, Italy. Treatment. All refractory GCA patients with or without involvement of aorta and its thoracic branches treated with intravenous TCZ at the dose of 8 mg/Kg/monthly or subcutaneous TCZ at the dose of 162 mg/weekly who achieved a stable remission over a 6-month period should receive reduced TCZ doses with the following schedules: intravenous TCZ tapering to 2 mg/Kg/monthly with drug withdrawal at month 4, and subcutaneous TCZ monthly reduction through the lengthening of injection intervals every 2, 3 , and 4 weeks, and with drug interruption at month 4.

Primary end-point. To investigate the maintenance of clinical remission after TCZ interruption over a 6-month follow-up period.

Secondary end-points. To assess the maintenance of clinical remission during the treatment, to evaluate the role of acute-phase reactants and PET in predicting the relapse and remission, and to assess the occurrence of adverse event (AEs).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Giant Cell Arteritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with GCA (ACR 1990 criteria)

At diagnosis, all GCA patients with or without involvement of aorta and its thoracic branches will receive PDN 50 mg/day and TCZ 8 mg/Kg/iv monthly. In all patients PDN dose will be reduced of 10 mg every 2 weeks until interruption at week 12.

Week 12. Subcutaneous TCZ 162 mg/weekly will be administered for additional 12 weeks.

Week 24. TCZ tapering every 8 weeks as follows:

* 1 injection every 2 weeks
* 1 injection every 3 weeks
* 1 injection every 4 weeks Week 48. TCZ withdrawal. Week 72. Remission evaluation.

Group Type EXPERIMENTAL

Tocilizumab

Intervention Type DRUG

Intravenous Tocilizumab followed by subcutaneousTocilizumab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tocilizumab

Intravenous Tocilizumab followed by subcutaneousTocilizumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- All consecutive patients meeting the 1990 ACR classification criteria for GCA.

Exclusion Criteria

* Corticosteroid treatment during the previous 6 months.
* Uncontrolled diabetes.
* Uncontrolled hypertension.
* History of cancer within the past 5 years.
* History of frequent infections in the past.
* Positivity of screening procedures for latent tuberculosis infection.
* Uncontrolled dyslipidemia at baseline.
* Known intestinal diverticulosis.
* Concomitant hematologic disorders.

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No